STOCK TITAN

Marex Group (MRX) CEO sells 37,142 shares, retains 2,803,960

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Marex Group Ltd Chief Executive Officer Ian T. Lowitt reported open-market sales of 37,142 ordinary shares on July 13, 2026, at prices ranging from $63.66 to $66.09, under a pre-arranged Rule 10b5-1 plan. After these transactions he directly holds 2,803,960 ordinary shares, including 194,411 underlying deferred bonus plan awards.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Lowitt Ian T
Role Chief Executive Officer
Sold 37,142 shs ($2.39M)
Type Security Shares Price Value
Sale Ordinary Shares 27,398 $64.1857 $1.76M
Sale Ordinary Shares 8,957 $64.9017 $581K
Sale Ordinary Shares 787 $65.8433 $52K
Holdings After Transaction: Ordinary Shares — 2,803,960 shares (Direct)
Footnotes (1)
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.66 to $64.6533, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.66 to $65.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.66 to $66.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
Shares sold 37,142 shares Total ordinary shares sold in open-market transactions on July 13, 2026
Lowest sale price $63.66 per share Lower end of price range for the July 13, 2026 sales
Highest sale price $66.09 per share Upper end of price range for the July 13, 2026 sales
Shares owned after transactions 2,803,960 shares Directly held Marex Group ordinary shares reported after July 13, 2026 sales
Deferred bonus plan awards 194,411 shares Ordinary shares underlying deferred bonus plan awards included within reported holdings
Rule 10b5-1 plan date March 12, 2026 Date Ian T. Lowitt entered the Rule 10b5-1 trading plan governing these sales
Rule 10b5-1 plan financial
"The sale reported ... was effected pursuant to a Rule 10b5-1 plan entered..."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
deferred bonus plan awards financial
"includes 194,411 shares underlying deferred bonus plan awards previously granted"
Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.
contingent right financial
"Each award represents a contingent right to receive one (1) ordinary share"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider share sales did Marex Group (MRX) report for CEO Ian T. Lowitt?

Ian T. Lowitt reported selling 37,142 Marex Group ordinary shares on July 13, 2026 in three open-market transactions. Sale prices fell within a $63.66–$66.09 range, and the trades were executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Marex Group (MRX) CEO Ian T. Lowitt sell his shares?

The reported weighted-average sale prices were around the mid-$60s, with individual trades occurring between $63.66 and $66.09 per share. Footnotes state the Column 4 prices are weighted averages and that detailed breakdowns by exact price within each range are available on request.

How many Marex Group (MRX) shares does CEO Ian T. Lowitt hold after these sales?

Following the July 13, 2026 transactions, Ian T. Lowitt is reported as directly owning 2,803,960 Marex Group ordinary shares. This figure includes 194,411 shares underlying deferred bonus plan awards that each represent a right to receive one ordinary share upon vesting and settlement.

Were the Marex Group (MRX) CEO’s July 2026 share sales pre-planned under a Rule 10b5-1 plan?

Yes. A footnote explains the sales were effected pursuant to a Rule 10b5-1 plan that Ian T. Lowitt entered on March 12, 2026. Such plans allow executives to schedule trades in advance, reducing the significance of trade timing as an information signal.

What are the deferred bonus plan awards mentioned for Marex Group (MRX) CEO Ian T. Lowitt?

His reported holdings include 194,411 shares underlying deferred bonus plan awards. Each award represents a contingent right to receive one ordinary share of Marex Group upon vesting and settlement, meaning part of his position is tied to future compensation vesting.

How many Marex Group (MRX) share sale transactions did the CEO report on July 13, 2026?

Ian T. Lowitt reported three separate open-market sale transactions in Marex Group ordinary shares on July 13, 2026. Together they totaled 37,142 shares sold, according to the transaction summary, all coded as open-market or private sales of non-derivative securities.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lowitt Ian T

(Last)(First)(Middle)
C/O MAREX GROUP LIMITED, 155 BISHOPSGATE

(Street)
LONDONUNITED KINGDOMEC2M 3TQ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Marex Group Ltd [ MRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares07/13/2026S(1)27,398D$64.1857(2)2,803,960D
Ordinary Shares07/13/2026S(1)8,957D$64.9017(3)2,795,003D
Ordinary Shares07/13/2026S(1)787D$65.8433(4)2,794,216(5)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on March 12, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.66 to $64.6533, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.66 to $65.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.66 to $66.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The number of ordinary shares reported herein includes 194,411 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.
/s/ Scott Linsley as Attorney-in-Fact, for Ian T. Lowitt07/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)